Fernand Labrie

Publications

Page 2 of 4, showing 50 records out of 191 total, starting on record 51, ending on 100

Publication Category Year
412. Picard, F., Deshaies, Y., Lalonde, J., Samson, P., Labrie, C., Bélanger, A., Labrie, F., Richard, D. (2000) Effects of the estrogen antagonist EM-652.HCl on energy balance and lipid metabolism in ovariectomized rats. Int. J. Obes. Relat. Metab. Disord., 24: 830-840. Breast Cancer 2000
360. Sourla, A., Richard, V., Labrie, F., Labrie, C. (2000) Exclusive androgenic effect of dehydroepiandrosterone in sebaceous glands of rat skin. J. Endocrinol., 166: 455-462. Breast Cancer 2000
414. The BRCA1 Exon 13 Duplication Screening Group. (2000) The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations. The BRCA1 Exon 13 Duplication Screening Group. Am J Hum Genet., 67: 207-212. Breast Cancer 2000
56. Boivin, R.P., Poirier, D., Labrie, F. (1999) 17alpha-alkan (or alkyn) amide derivatives of estradiol as inhibitors of steroid-sulfatase activity. Steroids, 64: 825-833. Breast Cancer 1999
416. Couillard, S., Gutman, M., Labrie, F., Candas, B., Labrie, C. (1999) Effect of the combined treatment with the pure antiestrogen EM-800 and radiotherapy on the growth of human ZR-75-1 breast cancer xenografts in nude mice. Cancer Res., 59: 4857-4863. Breast Cancer 1999
417. Gutman, M., Couillard, S., Labrie, F., Candas, B., Labrie, C. (1999) Effects of the antiestrogen EM-800 (SCH 57050) and cyclophosphamide alone and in combination on growth of human ZR-75-1 breast cancer xenografts in nude mice. Cancer Res., 59: 5176-5180. Breast Cancer 1999
418. Hida, N., Poulin, R., Veilleux, R., Labrie, F. (1999) Differential androgen sensitivity is associated with clonal heterogeneity in steroid metabolism, ornithine decarboxylase regulation and IL-1alpha action in mouse mammary tumor cells. J. Steroid Biochem. Mol. Biol., 71: 71-81. Breast Cancer 1999
61. Labrie, F., Bélanger, A., Simard, J., Luu-The, V., Labrie, C., Lin, S.-X., Candas, B., Cusan, L. (1999) Impact de l'intracrinologie dans la thérapeutique et la prévention des cancers du sein et de la prostate et de la ménopause, in: Guérité, N. et Leclère, J., eds: Mises au point cliniques d'endocrinologie, nutrition et métabolisme 1999, Paris, France, Les Éditions de Médecine Pratique, pp 169-204. Breast Cancer 1999
420. Labrie, F., Labrie, C., Bélanger, A., Simard, J., Gauthier, S., Luu-The, V., Mérand, Y., Giguère, V., Candas, B., Luo, S., Martel, C., Singh, S.M., Fournier, M., Coquet, A., Richard, V., Charbonneau, R., Charpenet, G., Tremblay, A., Tremblay, G., Cusan, L., Veilleux, R. (1999) EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium. J. Steroid Biochem. Mol. Biol., 69: 51-84. Breast Cancer 1999
421. Labrie, F.; (1999). EM-652: a pure anti-estrogen discovered and developed in Canada. The best hope for breast cancer prevention and treatment. Can. Breast Cancer Network, 4: Vol. 4, p. 7. Breast Cancer 1999
422. Pelletier, G., Luu-The, V., Charbonneau, A., Labrie, F. (1999) Cellular localization of estrogen receptor beta messenger ribonucleic acid in cynomolgus monkey reproductive organs. Biol. Reprod., 61: 1249-1255. Breast Cancer 1999
4726. Pelletier, G., Luu-The, V., Tetu, B., Labrie, F. (1999) Immunocytochemical localization of type 5 17beta-hydroxysteroid dehydrogenase in human reproductive tissues. J. Histochem Cytochem., 47: 731-738. Breast Cancer 1999
424. Tremblay, G.B., Tremblay, A., Labrie, F., Giguère, V. (1999) Dominant activity of activation function-1 (AF-1) and differential stoichiometric requirements for AF-1 and -2 in the estrogen receptor α⁄β heterodimeric complex. Mol. Cell. Biol., 19: 1919-1927. Breast Cancer 1999
425. Couillard, S., Gutman, M., Labrie, C., Bélanger, A., Candas, B., Labrie, F. (1998) Comparison of the effects of the antiestrogens EM-800 and Tamoxifen on the growth of human breast ZR-75-1 cancer xenografts in nude mice. Cancer Res., 58: 60-64. Breast Cancer 1998
426. Couillard, S., Labrie, C., Bélanger, A., Candas, B., Pouliot, F., Labrie, F. (1998) Effect of dehydroepiandrosterone and the antiestrogen EM-800 on growth of human ZR-75-1 breast cancer xenografts. J. Natl. Cancer Inst., 90: 772-778. Breast Cancer 1998
77. Labrie, F., Bélanger, A., Luu-The, V., Labrie, C., Simard, J., Cusan, L., Gomez, J.L., Candas, B. (1998) DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging. Steroids, 63: 322-328. Breast Cancer 1998
428. Luo, S., Labrie, C., Bélanger, A., Candas, B., Labrie, F. (1998) Prevention of development of dimenthylbenz(a)anthracene (DMBA)-induced mammary tumors in the rat by the new nonsteroidal antiestrogen EM-800 (SCH 57050). Breast Cancer Res. Treat., 49: 1-11. Breast Cancer 1998
429. Luo, S., Sourla, A., Labrie, C., Gauthier, S., Mérand, Y., Bélanger, A., Labrie, F. (1998) Effect of twenty-four-week treatment with the antiestrogen EM-800 on estrogen-sensitive parameters in intact and ovariectomized mice. Endocrinology, 139: 2645-2656. Breast Cancer 1998
430. Martel, C., Labrie, C., Bélanger, A., Gauthier, S., Mérand, Y., Li, X., Provencher, L., Candas, B., Labrie, F. (1998) Comparison of the effects of the new orally active antiestrogen EM-800 with ICI 182 780 and toremifene on estrogen-sensitive parameters in the ovariectomized mouse. Endocrinology, 139: 2486-2492. Breast Cancer 1998
431. Martel, C., Provencher, L., Li, X., St-Pierre, A., Leblanc, G., Gauthier, S., Mérand, Y., Labrie, F. (1998) Binding characteristics of novel nonsteroidal antiestrogens to the rat uterine estrogen receptors. J. Steroid Biochem. Mol. Biol., 64: 199-205. Breast Cancer 1998
432. Martel, C., Sourla, A., Pelletier, G., Labrie, C., Fournier, M., Picard, S., Li, S., Stojanovic, M., Labrie, F. (1998) Predominant androgenic component in the stimulatory effect of dehydroepiandrosterone on bone mineral density in the rat. J. Endocrinol., 157: 433-442. Breast Cancer 1998
433. Sourla, A., Martel, C., Labrie, C., Labrie, F. (1998) Almost exclusive androgenic action of dehydroepiandrosterone in the rat mammary gland. Endocrinology, 139: 753-764. Breast Cancer 1998
434. Tremblay, A., Tremblay, G.B., Labrie, C., Labrie, F., Giguère, V. (1998) EM-800, a novel antiestrogen, acts as a pure antagonist of the transcriptional functions of estrogen receptors α and beta. Endocrinology, 139: 111-118. Breast Cancer 1998
435. Tremblay, G.B., Tremblay, A., Labrie, F., Giguère, V. (1998) Ligand-independent activation of the estrogen receptors α and beta by mutations of a conserved tyrosine can be abolished by antiestrogens. Cancer Res., 58: 877-881. Breast Cancer 1998
436. Turgeon, C., Gingras, S., Carrière, M.C., Blais, Y., Labrie, F., Simard, J. (1998) Regulation of sex steroid formation by interleukin-4 and interleukin-6 in breast cancer cells. J. Steroid Biochem. Mol. Biol., 65: 151-162. Breast Cancer 1998
362. Durocher, F., Simard, J., Ouellette, J., Richard, V., Labrie, F., Pelletier, G. (1997) Localization of the BRCA1 gene expression in adult cynomolgus monkey tissues. J. Histochem. Cytochem., 45: 1173-1188. Breast Cancer 1997
438. Gauthier, S., Caron, B., Cloutier, J., Dory, Y.L., Favre, A., Larouche, D., Mailhot, J., Ouellet, C., Schwerdtfeger, A., Leblanc, G., Martel, C., Simard, J., Mérand, Y., Bélanger, A., Labrie, C., Labrie, F. (1997) (S)-(+)-[4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl) ethoxy]phenyl]-2H-1-benzopyran-3-yl]phenyl]-2,2-dimethylpropanoate (EM-800): a highly potent, specific and orally active non-steroidal antiestrogen. J. Med. Chem., 40: 2117-2122. Breast Cancer 1997
439. Luo, S., Labrie, C., Bélanger, A., Labrie, F. (1997) Effect of dehydroepiandrosterone (DHEA) on bone mass, serum lipids, and dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat. Endocrinology, 138: 3387-3394. Breast Cancer 1997
440. Luo, S., Martel, C., Gauthier, S., Mérand, Y., Bélanger, A., Labrie, C., Labrie, F. (1997) Long-term inhibitory effects of a novel anti-estrogen on the growth of ZR-75-1 and MCF-7 human breast cancer tumors in nude mice. Int. J. Cancer, 73: 735-739. Breast Cancer 1997
441. Luo, S., Martel, C., Sourla, A., Gauthier, S., Mérand, Y., Bélanger, A., Labrie, C., Labrie, F. (1997) Comparative effects of 28-day treatment with the new antiestrogen EM-800 and tamoxifen on estrogen-sensitive parameters in the intact mouse. Int. J. Cancer, 73: 381-391. Breast Cancer 1997
442. Luo, S., Sourla, A., Labrie, C., Bélanger, A., Labrie, F. (1997) Combined effects of dehydroepiandrosterone and EM-800 on bone mass, serum lipids, and the development of dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat. Endocrinology, 138: 4435-4444. Breast Cancer 1997
443. Luo, S., Stojanovic, M., Labrie, C., Labrie, F. (1997) Inhibitory effect of the novel antiestrogen EM-800 and medroxyprogesterone acetate (MPA) on estrone-stimulated growth of dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat. Int. J. Cancer, 73: 580-586. Breast Cancer 1997
444. Simard, J., Labrie, C., Bélanger, A., Gauthier, S., Singh, S.M., Mérand, Y., Labrie, F. (1997) Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro. Int. J. Cancer, 73: 104-112. Breast Cancer 1997
445. Simard, J., Sanchez, R., Poirier, D., Gauthier, S., Singh, S.M., Mérand, Y., Bélanger, A., Labrie, C., Labrie, F. (1997) Blockade of the stimulatory effect of estrogens, OH-Tamoxifen, OH-Toremifene, Droloxifene and Raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells. Cancer Res., 57: 3494-3497. Breast Cancer 1997
90. Simard, J., Singh, S.M., Labrie, F. (1997) Comparison of in vitro effects of the pure antiandrogens OH-Flutamide, Casodex and Nilutamide on androgen-sensitive parameters. Urology, 49: 580-589. Breast Cancer 1997
447. Sourla, A., Luo, S., Labrie, C., Bélanger, A., Labrie, F. (1997) Morphological changes induced by six-month treatment of intact and ovariectomized mice with tamoxifen and the pure antiestrogen EM-800. Endocrinology, 138: 5605-5617. Breast Cancer 1997
448. Tremblay, G.B., Tremblay, A., Copeland, N.G., Gilbert, D.J., Jenkins, N.A., Labrie, F., Giguère, V. (1997) Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta. Mol. Endocrinol., 11: 353-365. Breast Cancer 1997
91. Azzi, A., Rehse, P.H., Zhu, D.-W., Campbell, R.L., Labrie, F., Lin, S.-X. (1996) Crystal structure of human estrogenic 17beta-hydroxysteroid dehydrogenase complexed with 17beta-estradiol. Nat. Struct. Biol., 3: 665-668. Breast Cancer 1996
450. Blais, Y., Gingras, S., Haagensen, D.E., Labrie, F., Simard, J. (1996). Interleukin-4 and interleukin-13 inhibit estrogen-induced breast cancer cell proliferation and stimulate GCDFP-15 expression in human breast cancer cells. Mol. Cell. Endocrinol., 121: 11-18. Breast Cancer 1996
451. Blais, Y., Zhao, C., Huber, M., Audette, M., Labrie, F., Poulin, R. (1996) Growth-independent induction of spermidine transport by IL-4 and IL-13 in ZR-75-1 human breast cancer cells. Int. J. Cancer, 67: 532-538. Breast Cancer 1996
452. Couch, F.J., Rommens, J.M., Neuhausen, S.L., Bélanger, C., Dumont, M., Abel, K., Bell, R., Berry, S., Bogden, R., Cannon-Albright, L., Farid, L., Frye, C., Hattier, T., Janecki, T., Jiang, P., Kehrer, R., Leblanc, J.F., McArthur-Morrison, J., McSweeney, D., Miki, Y., Peng, Y., Samson, C., Schroeder, M., Snyder, S.C., Stringfellow, M., Stroup, C., Swedlund, B., Swensen, J., Teng, D., Thakur, S., Tran, T., Tranchant, M., Welver-Feldhaus, J., Wong, A.K.C., Sjoziua, J., Labrie, F., Skolnick, M.H., Goldgar, D.E., Kamb, A., Weber, B.L., Tavtigian, S.V., Simard, J. (1996) Generation of an integrated transcription map of the BRCA2 region on chromosome 13q12-q13. Genomics, 36: 86-99. Breast Cancer 1996
453. Durocher, F., Shattuck-Eidens, D., McClure, M., Labrie, F., Skolnick, M.H., Goldgar, D.E., Simard, J. (1996) Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations. Hum. Mol. Genet., 5: 835-842. Breast Cancer 1996
454. Poirier, D., Mérand, Y., Labrie, C., Labrie, F. (1996) D-Ring alkylamide derivatives of estradiol: Effect on ER-binding affinity and antiestrogenic activity. Bioorg. Med. Chem. Lett., 6: 2537-2542. Breast Cancer 1996
455. Tavtigian, S.V., Simard, J., Rommens, J., Couch, F., Shattuck-Eidens, D., Neuhausen, S., Merajver, S., Thorlacius, S., Offit, K., Stoppa-Lyonnet, D., Belanger, C., Bell, R., Berry, S., Bogden, R., Chen, Q., Davis, T., Dumont, M., Frye, C., Hattier, T., Jammulapati, S., Janecki, T., Jiang, P., Kehrer, R., Leblanc, J.-F., Mitchell, J.T., McArthur-Morrison, J., Nguyen, K., Peng, Y., Samson, C., Schroeder, M., Snyder, S.C., Steele, L., Stringfellow, M., Stroup, C., Swedlund, B., Swensen, J., Teng, D., Thomas, A., Tran, T., Tran, T., Tranchant, M., Weaver-Feldhaus, J., Wong, A.K.C., Shizuya, H., Eyfjord, J.E., Cannon-Albright, L., Labrie, F., Skolnick, M.H., Weber, B., Kamb, A., Goldgar, D.E. (1996) The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat. Genet., 12: 333-337. Breast Cancer 1996
456. Auger, S., Mérand, Y., Pelletier, J.D., Poirier, D., Labrie, F. (1995) Synthesis and biological activities of thioether derivatives related to the antiestrogens tamoxifen and ICI 164384. J. Steroid Biochem. Mol. Biol., 52: 547-565. Breast Cancer 1995
457. Blais, Y., Sugimoto, K., Carrière, M.C., Haagensen, D.E., Labrie, F., Simard, J. (1995) Interleukin-6 inhibits the potent stimulatory action of androgens, glucocorticoids and interleukin-1alpha on apolipoprotein D and GCDFP-15 expression in human breast cancer cells. Int. J. Cancer, 62: 732-737. Breast Cancer 1995
111. Labrie, F., Bélanger, A., Simard, J., Luu-The, V., Labrie, C. (1995) Intracrinologie: autonomie et liberté des tissus périphériques. Ann. Endocrinol. (Paris), 56: 23-29. Breast Cancer 1995
459. Labrie, F., Li, S., Labrie, C., Lévesque, C., Mérand, Y. (1995) Inhibitory effect of a steroidal antiestrogen (EM-170) on estrone-stimulated growth of 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat. Breast Cancer Res. Treat., 33: 237-244. Breast Cancer 1995
460. Li, S., Lévesque, C., Geng, C.S., Yan, X., Labrie, F. (1995) Inhibitory effects of medroxyprogesterone acetate (MPA) and the pure antiestrogen EM-219 on estrone (E1)-stimulated growth of dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat. Breast Cancer Res. Treat., 34: 147-159. Breast Cancer 1995
461. Shattuck-Eidens, D., McClure, M., simard, J., Labrie, F., Narod, S.A., Couch, F.J., Hoskins, K., Weber, B., Castilla, L., Erdos, M.E.A. (1995) A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene: implications of presymptomatic testing and screening. JAMA, 273: 535-541. Breast Cancer 1995
<< previous | 1 | 2 | 3 | 4 next >>

Biography  |  Publications  |  Scientific Conferences  |  Selected Slide Presentations  |  Awards